home / stock / amrx / amrx quote
Last: | $5.87 |
---|---|
Change Percent: | -0.17% |
Open: | $5.77 |
Close: | $5.87 |
High: | $5.95 |
Low: | $5.745 |
Volume: | 1,046,902 |
Last Trade Date Time: | 12/26/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.87 | $5.77 | $5.87 | $5.95 | $5.745 | 1,046,902 | 12-26-2023 |
$5.76 | $5.6 | $5.76 | $5.8 | $5.56 | 1,752,196 | 12-25-2023 |
$5.76 | $5.6 | $5.76 | $5.8 | $5.56 | 1,752,196 | 12-22-2023 |
$5.54 | $5.35 | $5.54 | $5.555 | $5.34 | 917,523 | 12-21-2023 |
$5.29 | $5.32 | $5.29 | $5.49 | $5.22 | 1,498,705 | 12-20-2023 |
$5.35 | $5.4 | $5.35 | $5.46 | $5.22 | 1,835,976 | 12-19-2023 |
$5.35 | $5.25 | $5.35 | $5.39 | $5.035 | 2,104,157 | 12-18-2023 |
$5.19 | $5.06 | $5.19 | $5.225 | $4.91 | 3,185,458 | 12-15-2023 |
$5 | $4.74 | $5 | $5.01 | $4.74 | 1,505,725 | 12-14-2023 |
$4.71 | $4.66 | $4.71 | $4.85 | $4.46 | 1,879,422 | 12-13-2023 |
$4.64 | $4.93 | $4.64 | $4.9549 | $4.63 | 1,123,281 | 12-12-2023 |
$4.9 | $5.1 | $4.9 | $5.1453 | $4.82 | 1,027,855 | 12-11-2023 |
$5.06 | $4.74 | $5.06 | $5.245 | $4.71 | 2,315,420 | 12-08-2023 |
$4.69 | $4.57 | $4.69 | $4.71 | $4.55 | 878,868 | 12-07-2023 |
$4.55 | $4.71 | $4.55 | $4.77 | $4.53 | 1,303,001 | 12-06-2023 |
$4.62 | $4.78 | $4.62 | $4.79 | $4.55 | 1,349,927 | 12-05-2023 |
$4.71 | $4.58 | $4.71 | $4.77 | $4.51 | 1,356,218 | 12-04-2023 |
$4.66 | $4.36 | $4.66 | $4.69 | $4.25 | 1,508,169 | 12-01-2023 |
$4.31 | $4.38 | $4.31 | $4.38 | $4.17 | 2,530,035 | 11-30-2023 |
$4.35 | $4.39 | $4.35 | $4.41 | $4.28 | 800,135 | 11-29-2023 |
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...